Vanderbilt Vaccine Research Program

VUMC begins study of second COVID-19 vaccine

Vanderbilt University Medical Center has begun recruiting up to 250 participants for a Phase 3 clinical trial testing an investigational COVID-19 vaccine candidate developed by the Janssen Pharmaceutical Companies of Johnson & Johnson.

Remdesivir helps reduce COVID-19 recovery time: study

The investigational antiviral drug remdesivir can shorten the time to recovery in adults hospitalized with COVID-19, according to preliminary results of a clinical trial published last month in The New England Journal of Medicine.

Vanderbilt investigators encouraged by early results of placebo-controlled remdesivir trial

A preliminary look at data from hospitalized adults diagnosed with coronavirus disease 2019 (COVID-19) in a randomized, controlled clinical trial to evaluate the safety and efficacy of the investigational antiviral remdesivir is showing promising results.

Vials with medication and syringe on blue methacrylate table. Horizontal composition. Top elevated view.

Vaccine Program receives NIH renewal of VTEU

The Vanderbilt Vaccine Research Program has received a grant from the NIH to continue its work as one of the nation’s nine Vaccine and Treatment Evaluation Units.

Vials with medication and syringe on blue methacrylate table. Horizontal composition. Top elevated view.

Vaccine Program receives NIH renewal of VTEU

The Vanderbilt Vaccine Research Program (VVRP) has received a grant from the National Institutes of Health (NIH) to continue its work as one of the nation’s nine Vaccine and Treatment Evaluation Units (VTEUs).

Man holds his hand over his mouth while coughing into it

Nasal whooping cough vaccine trial underway at Vanderbilt

Vanderbilt vaccine researchers are enrolling adult volunteers in a National Institutes of Health (NIH)-sponsored Phase II clinical trial that will study a next generation pertussis vaccine that may protect people from whooping cough.

1 2 3